Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Gent – page 15

899 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance
899
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

899 trials in Gent

Open in trial search

Acromegaly

Recruiting

Study of Debio 4126, a new octreotide formulation, compared to placebo in patients with acromegaly who were previously treated with somatostatin analogs

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Debiopharm International SA

Neoplasm

Recruiting

Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Stargardt's disease

Recruiting

Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
  • Sponsor:Splicebio S.L.

Cardiac failure

Recruiting

Evaluating the Effect of Vicadrostat and Empagliflozin Combination Compared to Empagliflozin Alone in Patients with Heart Failure and Reduced Left Ventricular Function

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan, Rilvegostomig, and Pembrolizumab for Advanced or Recurrent Endometrial Cancer in HER2-Positive Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Primary biliary cholangitis

Recruiting

Study of Seladelpar Treatment in Patients with Primary Biliary Cholangitis and Compensated Cirrhosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Seladelpar
  • Sponsor:Gilead Sciences Inc.

Ischaemic stroke

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:JX10
  • Sponsor:Corxel Pharmaceuticals Co. Ltd.

Meningococcal immunisation

Recruiting

Study on Immune Response Differences to Meningococcal Group B Vaccine in Healthy Transgender and Cisgender Adults Aged 18-40

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:Outer Membrane Vesicles (Omv) From Neisseria Meningitidis Group B Strain Nz98/254 Measured As Amount Of Total Protein Containing The Pora P1.4 Adsorbed On Aluminium Hydroxide
  • Sponsor:Universiteit Gent

Autologous haematopoietic stem cell transplant

Recruiting

Study Comparing Two Drug Combinations for Blood Cancer Patients: Rabbit Anti-Human Thymocyte Immunoglobulin vs. Anhydrous Cyclophosphamide

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Anhydrous Cyclophosphamide
  • Sponsor:Centre hospitalier universitaire de Liege

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

  • Influenza vaccine studies for adults 65+
  • RSV vaccine development
  • Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

  • Nasal decongestant dependency treatment
  • Chronic rhinosinusitis management
  • Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

  • Primary biliary cholangitis treatment
  • Psoriasis therapies
  • Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.